Table 2.
Any treatment received and time to treatment (Commercial and Medicaid populations; 12-month follow-up, by age)
| Age category | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 18–24 years | 25–29 years | 30–34 years | 35–39 years | 40–44 years | 45–49 years | 50–54 years | 55–59 years | 60–64 years | |
| Commercial population (n = 225,737) | |||||||||
| n | 1532 | 5485 | 19,562 | 40,403 | 62,861 | 58,717 | 25,741 | 7494 | 3942 |
| Any treatment, n (%) | 1114 (72.7) | 4161 (75.9) | 14,307 (73.1) | 29,570 (73.2) | 45,557 (72.5) | 40,144 (68.4) | 14,788 (57.4) | 3220 (43.0) | 1505 (38.2) |
| Mean (SD) time to first treatmenta, days | 57.0 (82.4) | 63.6 (87.2) | 62.5 (88.4) | 57.3 (83.1) | 53.1 (78.3) | 53.8 (78.7) | 58.7 (84.5) | 76.7 (96.9) | 76.4 (97.4) |
| Pharmacologic treatment | 61.9 (85.5) | 72.1 (92.2) | 76.7 (96.5) | 76.1 (94.7) | 72.8 (91.4) | 76.1 (93.7) | 90.1 (101.1) | 117.1 (107.6) | 116.9 (107.4) |
| Surgical treatment | 30.1 (55.8) | 42.2 (68.6) | 39.3 (67.1) | 37.9 (63.5) | 38.5 (63.2) | 39.1 (62.9) | 37.1 (62.2) | 35.3 (61.5) | 26.7 (49.9) |
| Mean (SD) time to second treatment, days | 129.8 (102.2) | 129.4 (108.4) | 117.6 (105.2) | 106.2 (102.3) | 99.7 (99.2) | 95.0 (97.2) | 92.5 (97.9) | 82.5 (94.6) | 90.3 (98.7) |
| Pharmacologicb, n (%) | |||||||||
| Any | 1052 (68.7) | 3745 (68.3) | 12,156 (62.1) | 23,047 (57.0) | 33,028 (52.5) | 27,850 (47.4) | 10,096 (39.2) | 2362 (31.5) | 1121 (28.4) |
| Aromatase inhibitor | 5 (0.3) | 98 (1.8) | 311 (1.6) | 391 (1.0) | 226 (0.4) | 29 (< 0.1) | 4 (< 0.1) | 2 (< 0.1) | 0 (0.0) |
| Danazol | 1 (0.1) | 0 (0.0) | 15 (0.1) | 11 (< 0.1) | 23 (< 0.1) | 11 (< 0.1) | 4 (< 0.1) | 1 (< 0.1) | 0 (0.0) |
| Dopamine promoter | 2 (0.1) | 20 (0.4) | 117 (0.6) | 146 (0.4) | 118 (0.2) | 76 (0.1) | 24 (0.1) | 6 (0.1) | 0 (0.0) |
| GnRH agonist | 45 (2.9) | 185 (3.4) | 617 (3.2) | 929 (2.3) | 1048 (1.7) | 780 (1.3) | 263 (1.0) | 13 (0.2) | 0 (0.0) |
| Hormonal contraceptivec | 829 (54.1) | 2351 (42.9) | 6187 (31.6) | 9206 (22.8) | 10,290 (16.4) | 6840 (11.6) | 1583 (6.1) | 70 (0.9) | 8 (0.2) |
| Iron supplement | 49 (3.2) | 330 (6.0) | 1002 (5.1) | 1249 (3.1) | 816 (1.3) | 286 (0.5) | 71 (0.3) | 8 (0.1) | 3 (0.1) |
| NSAID | 493 (32.2) | 2189 (39.9) | 7714 (39.4) | 16,310 (40.4) | 25,289 (40.2) | 22,482 (38.3) | 8656 (33.6) | 2243 (29.9) | 1065 (27.0) |
| SERM | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 9 (< 0.1) | 12 (< 0.1) | 33 (0.1) | 54 (0.7) | 65 (1.6) |
| Tranexamic acid | 13 (0.8) | 66 (1.2) | 261 (1.3) | 610 (1.5) | 1010 (1.6) | 939 (1.6) | 331 (1.3) | 17 (0.2) | 0 (0.0) |
| Surgicalb, n (%) | |||||||||
| Any | 254 (16.6) | 1695 (30.9) | 7399 (37.8) | 18,524 (45.8) | 32,251 (51.3) | 29,177 (49.7) | 10,175 (39.5) | 1740 (23.2) | 724 (18.4) |
| Ablation | 15 (1.0) | 114 (2.1) | 650 (3.3) | 2355 (5.8) | 4932 (7.8) | 4915 (8.4) | 1477 (5.7) | 94 (1.3) | 17 (0.4) |
| Hysterectomy | 23 (1.5) | 366 (6.7) | 2874 (14.7) | 10,723 (26.5) | 22,661 (36.0) | 21,570 (36.7) | 7822 (30.4) | 1500 (20.0) | 627 (15.9) |
| Myomectomy | 219 (14.3) | 1248 (22.8) | 3908 (20.0) | 5555 (13.7) | 4703 (7.5) | 2715 (4.6) | 950 (3.7) | 152 (2.0) | 81 (2.1) |
| Myomectomy and ablation | 5 (0.3) | 30 (0.5) | 120 (0.6) | 371 (0.9) | 722 (1.1) | 767 (1.3) | 217 (0.8) | 20 (0.3) | 4 (0.1) |
| Uterine artery embolization | 4 (0.3) | 18 (0.3) | 177 (0.9) | 577 (1.4) | 1244 (2.0) | 1243 (2.1) | 326 (1.3) | 37 (0.5) | 4 (0.1) |
| Medicaid population (n = 19,062) | |||||||||
| n | 593 | 1631 | 3385 | 4583 | 4340 | 2976 | 1017 | 379 | 158 |
| Any treatment, n (%) | 468 (78.9) | 1380 (84.6) | 2860 (84.5) | 3828 (83.5) | 3589 (82.7) | 2389 (80.3) | 728 (71.6) | 234 (61.7) | 98 (62.0) |
| Mean (SD) time to first treatmenta, days | 66.4 (87.1) | 58.7 (86.8) | 53.7 (80.4) | 51.5 (76.5) | 52.0 (76.2) | 57.0 (80.9) | 58.1 (82.8) | 71.0 (82.1) | 86.4 (98.6) |
| Pharmacologic treatment | 70.9 (89.1) | 70.0 (93.8) | 65.2 (88.8) | 64.1 (85.5) | 64.6 (85.7) | 66.1 (86.5) | 69.7 (91.6) | 82.1 (87.3) | 109.4 (104.6) |
| Surgical treatment | 23.5 (46.5) | 23.9 (45.3) | 29.8 (51.8) | 31.6 (53.7) | 33.1 (53.9) | 42.5 (68.4) | 37.0 (58.4) | 35.7 (48.8) | 31.6 (51.6) |
| Mean (SD) time to second treatment, days | 143.0 (109.9) | 119.5 (102.7) | 111.1 (102.7) | 99.0 (96.5) | 98.1 (96.8) | 101.9 (98.8) | 97.8 (97.3) | 99.0 (104.6) | 106.9 (85.7) |
| Pharmacologicb, n (%) | |||||||||
| Any | 459 (77.4) | 1307 (80.1) | 2622 (77.5) | 3459 (75.5) | 3196 (73.6) | 2127 (71.5) | 640 (62.9) | 218 (57.5) | 89 (56.3) |
| Aromatase inhibitor | 1 (0.2) | 1 (0.1) | 3 (0.1) | 4 (0.1) | 5 (0.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Danazol | 0 (0.0) | 1 (0.1) | 3 (0.1) | 2 (< 0.1) | 1 (< 0.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Dopamine promoter | 0 (0.0) | 1 (< 0.1) | 3 (0.1) | 2 (< 0.1) | 8 (0.2) | 1 (< 0.1) | 0 (0.0) | 1 (0.3) | 0 (0.0) |
| GnRH agonist | 18 (3.0) | 41 (2.5) | 71 (2.1) | 88 (1.9) | 74 (1.7) | 54 (1.8) | 8 (0.8) | 2 (0.5) | 0 (0.0) |
| Hormonal contraceptivec | 258 (43.5) | 573 (35.1) | 819 (24.2) | 826 (18.0) | 532 (12.3) | 252 (8.5) | 28 (2.8) | 4 (1.1) | 0 (0.0) |
| Iron supplement | 111 (18.7) | 261 (16.0) | 508 (15.0) | 762 (16.6) | 719 (16.6) | 489 (16.4) | 141 (13.9) | 20 (5.3) | 3 (1.9) |
| NSAID | 349 (58.9) | 1035 (63.5) | 2191 (64.7) | 2961 (64.6) | 2756 (63.5) | 1882 (63.2) | 573 (56.3) | 205 (54.1) | 87 (55.1) |
| SERM | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (< 0.1) | 4 (0.4) | 0 (0.0) | 1 (0.6) |
| Tranexamic acid | 1 (0.2) | 11 (0.7) | 37 (1.1) | 40 (0.9) | 46 (1.1) | 21 (0.7) | 2 (0.2) | 0 (0.0) | 0 (0.0) |
| Surgicalb, n (%) | |||||||||
| Any | 65 (11.0) | 465 (28.5) | 1308 (38.6) | 2071 (45.2) | 2060 (47.5) | 1282 (43.1) | 328 (32.3) | 69 (18.2) | 32 (20.3) |
| Ablation | 15 (2.5) | 70 (4.3) | 212 (6.3) | 344 (7.5) | 366 (8.4) | 194 (6.5) | 30 (2.9) | 3 (0.8) | 0 (0.0) |
| Hysterectomy | 28 (4.7) | 323 (19.8) | 973 (28.7) | 1568 (34.2) | 1575 (36.3) | 1005 (33.8) | 269 (26.5) | 63 (16.6) | 28 (17.7) |
| Myomectomy | 25 (4.2) | 81 (5.0) | 142 (4.2) | 163 (3.6) | 124 (2.9) | 57 (1.9) | 18 (1.8) | 4 (1.1) | 4 (2.5) |
| Myomectomy and ablation | 0 (0.0) | 4 (0.2) | 9 (0.3) | 30 (0.7) | 28 (0.6) | 15 (0.5) | 0 (0.0) | 2 (0.5) | 0 (0.0) |
| Uterine artery embolization | 1 (0.2) | 9 (0.6) | 32 (0.9) | 73 (1.6) | 80 (1.8) | 64 (2.2) | 16 (1.6) | 1 (0.3) | 0 (0.0) |
GnRH gonadotropin-releasing hormone, IUD intrauterine device, NSAID non-steroidal anti-inflammatory drug, SD standard deviation, SERM selective estrogen receptor modulator
aTime from index date
bWomen could receive multiple treatments in the 12 months post-index; therefore, individual values may total > 100%
cIncludes IUD/levonorgestrel implants, oral contraceptives, and other contraceptives; hormonal contraceptives were not mutually exclusive and a patient could receive > 1 type